News & Updates

The selective oral PARP1/2 inhibitor pamiparib is well tolerated and demonstrates favourable antitumour activity with durable responses in the treatment of patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer harbouring the germline BRCA mutation, according to the results of a phase II trial.

Pretreatment with the cyclin-dependent kinase 4/6 inhibitor trilaciclib appears to enhance the antitumour efficacy of gemcitabine plus carboplatin, with significant survival gains for patients with metastatic triple-negative breast cancer (mTNBC), according to the results of a phase II trial.

In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.

The risk of colorectal cancer (CRC) is heightened in patients with serrated polyposis syndrome (SPS) and their first-degree relatives (FDRs), according to a study, which confirms findings of other reports. In addition, those with sessile serrated lesions (SSL) are at higher of prostate cancer.

Therapy-naïve patients with haematological malignancies are able to mount a stronger immune response to the coronavirus disease 2019 (COVID-19), a recent study has found.

In heavily pretreated, lenalidomide-refractory patients with relapsed-refractory multiple myeloma (RRMM) and prior exposure to proteasome inhibitors, ixazomib dexamethasone may be an effective and tolerable treatment approach, leading to comparable health-related quality of life outcomes as pomalidomide-dexamethasone, a recent study has found.

Patient-reported outcome measures may help predict healthcare utilization, such as emergency department visits or unplanned hospitalizations, among patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), a recent study has found.

CT-P6, a trastuzumab biosimilar approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), is as efficacious as reference trastuzumab in terms of response rates, progression-free (PFS) and overall survival (OS), a study has shown.